Identification of small-molecule glucokinase activator for type-2-diabetes treatment: a structure-based virtual screening approach-Reference-Cited by-同舟云学术

Identification of small-molecule glucokinase activator for type-2-diabetes treatment: a structure-based virtual screening approach

Published:2023-09-14 Issue:17 Volume:49 Page:1596-1613
ISSN:0892-7022
Container-title:Molecular Simulation
language:en
Short-container-title:Molecular Simulation

Author:

Malini Manokaran¹,Thilagavathi Ramasamy¹,Vennila Jannet²,Malgija Beutline²,Praveena Gandhi³,Selvam Chelliah⁴

Affiliation:

1. Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore, India

2. MCC-MRF Innovation Park, Madras Christian College, Chennai, India

3. Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, India

4. Department of Pharmaceutical Sciences, Joan M. Lafleur College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA

Publisher

Informa UK Limited

Subject

Condensed Matter Physics,General Materials Science,General Chemical Engineering,Modeling and Simulation,Information Systems,General Chemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/08927022.2023.2256425

Reference58 articles.

1. Discovery of cycloalkyl-fused N -thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

2. Design, synthesis, and evaluation of some novel N-benzothiazol-2-yl benzamide derivatives as allosteric activators of human glucokinase;Arora S;J Appl Pharm Sci,2021

3. Recent advances in glucokinase activators for the treatment of type 2 diabetes

4. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus

5. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus